Will inter partes review speed US generic drug entry?

A new extra-judicial pathway for challenging pharmaceutical patents has intensified patent challenges and helped to clear the way for earlier generic entry.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Leahy-Smith America Invents Act, Pub. L. No. 112–29, 125 Stat. 284 (2011).

  2. 2

    21 USC § 355(j)(2)(vii)(IV) (2017).

  3. 3

    Grabowski, H. et al. J. Med. Econ. 19, 836–844 (2016).

  4. 4

    Goldstein, R.W. & Pentcheva, D.P. 2015 Report of the Economic Survey. AIPLA (June 2015).

  5. 5

    Gleaton, A.V. et al. Finnegan http://www.finnegan.com/resources/articles/articlesdetail.aspx?news=ef284b32-7634-4bc3-b718-7d387a8bc57f (7 March, 2014).

  6. 6

    37 CFR § 42.100(b) (2016).

  7. 7

    Phillips v. AWH Corp., 415 F.3d 1303, 1314 (Fed. Cir. 2005) (en banc).

  8. 8

    Duffy, J.F. George Washington Law Rev. 83, 28–46 (2015).

  9. 9

    Unified Patents. https://www.unifiedpatents.com/join

  10. 10

    Shuchman, L. Corp Counsel http://www.corpcounsel.com/id=1202751772701/In-a-Win-for-Crusaders-Bass-and-Spangenberg-PTO-Agrees-to-Reconsider-Pharma-Patents?slreturn=20160628073542 (9 March, 2016).

  11. 11

    Judgment on request for adverse judgment, Lupin Limited v. Vertex Pharm. Inc., IPR2015–00405, Paper No. 28 (PTAB 3 November, 2015).

  12. 12

    Final written decision, Lupin Limited v. Vertex Pharm. Inc., No. IPR2016–00558, Paper No. 39 (PTAB 2 August, 2016).

  13. 13

    Allergan, Inc. v. Teva Pharm. USA, Inc., No. 2:15-cv-1455-WCB, 2017 WL 4619790 (E.D. Tex. 16 October, 2017) (Bryson, J.).

  14. 14

    Lewis v. Clarke, 137 S. Ct. 1285 (2017).

  15. 15

    S. 1948, 115th Cong. 1st Sess. (5 October, 2017).

  16. 16

    Oil States Energy Servs., LLC v. Greene's Energy Grp., LLC, 137 S. Ct. 2239 (2017).

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jonathan J Darrow.

Ethics declarations

Competing interests

A.S.K. work is supported by the Laura and John Arnold Foundation, with additional support from the Harvard Program in Therapeutic Science and the Engelberg Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Darrow, J., Beall, R. & Kesselheim, A. Will inter partes review speed US generic drug entry?. Nat Biotechnol 35, 1139–1141 (2017). https://doi.org/10.1038/nbt.4036

Download citation

Further reading